Latest technologies from Burnham Institutehttp://burnhamott.technologypublisher.comBe the first to know about the latest inventions and technologies available from Burnham Instituteen-USThu, 11 Mar 2010 10:18:29 GMTFri, 12 Feb 2010 12:16:11 GMThttp://blogs.law.harvard.edu/tech/rssccurchoe@burnham.orgCopyright 2010, Burnham InstituteEphB Receptor-binding Peptideshttp://burnhamott.technologypublisher.com/technology/4652Fri, 12 Feb 2010 12:16:11 GMTccurchoe@burnham.orghttp://burnhamott.technologypublisher.com/technology/4652Tumor targeting peptideshttp://burnhamott.technologypublisher.com/technology/4651Fri, 12 Feb 2010 10:57:22 GMTccurchoe@burnham.orghttp://burnhamott.technologypublisher.com/technology/4651Eph A2/4 inhibitorshttp://burnhamott.technologypublisher.com/technology/4345Tue, 15 Dec 2009 16:55:41 GMTccurchoe@burnham.orghttp://burnhamott.technologypublisher.com/technology/4345Cardiotoxic drug screening assayhttp://burnhamott.technologypublisher.com/technology/4344Tue, 15 Dec 2009 13:51:37 GMTccurchoe@burnham.orghttp://burnhamott.technologypublisher.com/technology/4344Antibodies to West Nile virus infectionhttp://burnhamott.technologypublisher.com/technology/4343Tue, 15 Dec 2009 13:51:37 GMTccurchoe@burnham.orghttp://burnhamott.technologypublisher.com/technology/4343Modulators of Kaposis sarcoma-associated herpes virus latencyhttp://burnhamott.technologypublisher.com/technology/4279 Kaposi’s sarcoma-associated herpesvirus (KSHV), also known as human herpesvirus-8, is associated not only with B-lymphoproliferative diseases such as primary effusion lymphoma, but also with Kaposi’s sarcoma. Infection with KSHV normally results in a latent status where the viral genome is maintained as an episome in the nuclei of infected cells. In KSHV latent cells, lytic replication can be activated upon stimulation of cytokines or chemicals mediated by the immediate-early transactivator, Rta. Reactivation from latency to lytic replication is essential for transmission from host ...Mon, 14 Dec 2009 12:41:46 GMTccurchoe@burnham.orghttp://burnhamott.technologypublisher.com/technology/4279Targeting of albumin-embedded taxol nanoparticles to tumorshttp://burnhamott.technologypublisher.com/technology/3554Thu, 29 Oct 2009 16:06:40 GMTccurchoe@burnham.orghttp://burnhamott.technologypublisher.com/technology/3554Apogossypolone anticancer agentshttp://burnhamott.technologypublisher.com/technology/3553Thu, 29 Oct 2009 16:06:39 GMTccurchoe@burnham.orghttp://burnhamott.technologypublisher.com/technology/35533-CL-AHPN, an apoptosis inducerhttp://burnhamott.technologypublisher.com/technology/3503Fri, 09 Oct 2009 14:54:17 GMTccurchoe@burnham.orghttp://burnhamott.technologypublisher.com/technology/3503Cell migration inhibitorshttp://burnhamott.technologypublisher.com/technology/3502Fri, 09 Oct 2009 14:54:14 GMTccurchoe@burnham.orghttp://burnhamott.technologypublisher.com/technology/3502Cell adhesion receptor modifiershttp://burnhamott.technologypublisher.com/technology/3501Fri, 09 Oct 2009 14:54:14 GMTccurchoe@burnham.orghttp://burnhamott.technologypublisher.com/technology/3501Combinations of matrix ligandshttp://burnhamott.technologypublisher.com/technology/3500Fri, 09 Oct 2009 14:54:14 GMTccurchoe@burnham.orghttp://burnhamott.technologypublisher.com/technology/3500Antibodies to Integrinshttp://burnhamott.technologypublisher.com/technology/3499Fri, 09 Oct 2009 14:54:13 GMTccurchoe@burnham.orghttp://burnhamott.technologypublisher.com/technology/3499Extracellular matrix inhibitorshttp://burnhamott.technologypublisher.com/technology/3498Fri, 09 Oct 2009 14:54:13 GMTccurchoe@burnham.orghttp://burnhamott.technologypublisher.com/technology/3498Fibronectin receptor ligandshttp://burnhamott.technologypublisher.com/technology/3497Fri, 09 Oct 2009 14:54:13 GMTccurchoe@burnham.orghttp://burnhamott.technologypublisher.com/technology/3497Cell adhesion modulatorshttp://burnhamott.technologypublisher.com/technology/3496Fri, 09 Oct 2009 14:54:12 GMTccurchoe@burnham.orghttp://burnhamott.technologypublisher.com/technology/3496E-selectin cell adhesion modulatorshttp://burnhamott.technologypublisher.com/technology/3495Fri, 09 Oct 2009 14:54:11 GMTccurchoe@burnham.orghttp://burnhamott.technologypublisher.com/technology/3495EGFR expression in microsatellite instability colon cancershttp://burnhamott.technologypublisher.com/technology/3488Thu, 01 Oct 2009 14:52:18 GMTccurchoe@burnham.orghttp://burnhamott.technologypublisher.com/technology/3488Apoptosis modulatorshttp://burnhamott.technologypublisher.com/technology/3486Wed, 30 Sep 2009 16:53:04 GMTccurchoe@burnham.orghttp://burnhamott.technologypublisher.com/technology/3486HNF4a antagonistshttp://burnhamott.technologypublisher.com/technology/3469Tue, 29 Sep 2009 11:24:04 GMTccurchoe@burnham.orghttp://burnhamott.technologypublisher.com/technology/3469Artherosclerosis treatmentshttp://burnhamott.technologypublisher.com/technology/3468Tue, 29 Sep 2009 11:21:28 GMTccurchoe@burnham.orghttp://burnhamott.technologypublisher.com/technology/3468Nanoparticle delivery of clot binding compoundshttp://burnhamott.technologypublisher.com/technology/3467Tue, 29 Sep 2009 11:21:28 GMTccurchoe@burnham.orghttp://burnhamott.technologypublisher.com/technology/3467Synthetic Anthrax Vaccinehttp://burnhamott.technologypublisher.com/technology/3391Fri, 28 Aug 2009 15:36:03 GMTccurchoe@burnham.orghttp://burnhamott.technologypublisher.com/technology/3391Stem cell culture, differentiation and reprogramminghttp://burnhamott.technologypublisher.com/technology/3345Thu, 20 Aug 2009 17:20:54 GMTccurchoe@burnham.orghttp://burnhamott.technologypublisher.com/technology/3345Bladder tumor targeting peptideshttp://burnhamott.technologypublisher.com/technology/3344Thu, 20 Aug 2009 17:07:56 GMTccurchoe@burnham.orghttp://burnhamott.technologypublisher.com/technology/3344